Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.

Lamba JK, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimondi SC, Campana D, Pui CH, Downing JR, Rubnitz JE, Ribeiro RC.

Pharmacogenomics. 2011 Mar;12(3):327-39. doi: 10.2217/pgs.10.191.

PMID:
21449673
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.

Gamazon ER, Lamba JK, Pounds S, Stark AL, Wheeler HE, Cao X, Im HK, Mitra AK, Rubnitz JE, Ribeiro RC, Raimondi S, Campana D, Crews KR, Wong SS, Welsh M, Hulur I, Gorsic L, Hartford CM, Zhang W, Cox NJ, Dolan ME.

Blood. 2013 May 23;121(21):4366-76. doi: 10.1182/blood-2012-10-464149. Epub 2013 Mar 28.

PMID:
23538338
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Pharmacogenomics of cytarabine in childhood leukemia.

Lamba JK.

Pharmacogenomics. 2011 Dec;12(12):1629-32. doi: 10.2217/pgs.11.148. No abstract available.

PMID:
22118048
[PubMed - indexed for MEDLINE]
4.

Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.

Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, Zaberezhnyy V, Patel PR, Gao D, Tan AC, DeGregori J.

Leukemia. 2012 Jun;26(6):1266-76. doi: 10.1038/leu.2011.392. Epub 2012 Jan 13.

PMID:
22289989
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.

Falk IJ, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Höglund M, Palmqvist L, Stockelberg D, Wei Y, Gréen H, Lotfi K.

Am J Hematol. 2013 Dec;88(12):1001-6. doi: 10.1002/ajh.23549. Epub 2013 Sep 9.

PMID:
23873772
[PubMed - indexed for MEDLINE]
6.

Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.

Russ AC, Sander S, Lück SC, Lang KM, Bauer M, Rücker FG, Kestler HA, Schlenk RF, Döhner H, Holzmann K, Döhner K, Bullinger L.

Haematologica. 2011 Dec;96(12):1783-91. doi: 10.3324/haematol.2011.046888. Epub 2011 Aug 31.

PMID:
21880628
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia.

Yin B, Tsai ML, Hasz DE, Rathe SK, Le Beau MM, Largaespada DA.

Leukemia. 2007 May;21(5):1093-7. Epub 2007 Feb 15. No abstract available. Retraction in: Leukemia. 2010 Aug;24(8):1543.

PMID:
17301810
[PubMed - indexed for MEDLINE]
8.

No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Cahn JY, Labopin M, Sierra J, Blaise D, Reiffers J, Ferrant A, Bergmann L, Visani G, Cornelissen J, De Witte T, Bosi A, Frassoni F, Gorin NC.

Br J Haematol. 2000 Aug;110(2):308-14.

PMID:
10971386
[PubMed - indexed for MEDLINE]
9.

Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia.

Heuser M, Wingen LU, Steinemann D, Cario G, von Neuhoff N, Tauscher M, Bullinger L, Krauter J, Heil G, Döhner H, Schlegelberger B, Ganser A.

Haematologica. 2005 Nov;90(11):1484-92.

PMID:
16266895
[PubMed - indexed for MEDLINE]
Free Article
10.

Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.

Rao AV, Valk PJ, Metzeler KH, Acharya CR, Tuchman SA, Stevenson MM, Rizzieri DA, Delwel R, Buske C, Bohlander SK, Potti A, Löwenberg B.

J Clin Oncol. 2009 Nov 20;27(33):5580-6. doi: 10.1200/JCO.2009.22.2547. Epub 2009 Oct 26.

PMID:
19858393
[PubMed - indexed for MEDLINE]
Free Article
11.
12.
13.

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

J Clin Oncol. 2012 Sep 1;30(25):3109-18. doi: 10.1200/JCO.2011.40.6652. Epub 2012 Jul 2.

PMID:
22753902
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.

Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, Bloomfield CD.

J Clin Oncol. 1999 Dec;17(12):3767-75.

PMID:
10577848
[PubMed - indexed for MEDLINE]
15.

Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.

Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, Yabe H, Nakayama H, Kudo K, Kobayashi R, Hamamoto K, Imaizumi M, Morimoto A, Tsuchiya S, Hanada R.

J Clin Oncol. 2009 Aug 20;27(24):4007-13. doi: 10.1200/JCO.2008.18.7948. Epub 2009 Jul 20.

PMID:
19620491
[PubMed - indexed for MEDLINE]
Free Article
16.

Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).

Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, von Neuhoff C, Sander A, Schrauder A, Teigler-Schlegel A, Stary J, Corbacioglu S, Reinhardt D.

Blood. 2011 Nov 17;118(20):5409-15. doi: 10.1182/blood-2011-07-364661. Epub 2011 Sep 26.

PMID:
21948298
[PubMed - indexed for MEDLINE]
Free Article
17.

Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.

Hu XM, Liu F, Zheng CM, Li L, Liu C, Zhang SS, Xiao HY, Yang XH, Wang HZ, Xu YG, Hu NP, Ma R.

Chin J Integr Med. 2009 Jun;15(3):193-7. doi: 10.1007/s11655-009-0193-x. Epub 2009 Jul 2.

PMID:
19568712
[PubMed - indexed for MEDLINE]
18.

Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.

Hu XF, Slater A, Kantharidis P, Rischin D, Juneja S, Rossi R, Lee G, Parkin JD, Zalcberg JR.

Blood. 1999 Jun 15;93(12):4086-95.

PMID:
10361105
[PubMed - indexed for MEDLINE]
Free Article
19.

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.

Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC, Biemond B, Sonneveld P, Passweg J, Verdonck L, Legdeur MC, Theobald M, Jacky E, Bargetzi M, Maertens J, Ossenkoppele GJ, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German AML Study Group (AMLSG); Swiss Collaborative Group for Clinical Cancer Research (SAKK).

Blood. 2012 Jun 7;119(23):5367-73. doi: 10.1182/blood-2011-11-389841. Epub 2012 Mar 15.

PMID:
22422824
[PubMed - indexed for MEDLINE]
Free Article
20.

Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts.

Illmer T, Thiede C, Fredersdorf A, Stadler S, Neubauer A, Ehninger G, Schaich M.

Clin Cancer Res. 2005 May 1;11(9):3217-24.

PMID:
15867216
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk